CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) has issued an announcement.
CARsgen Therapeutics Holdings Limited announced that their research results on satricabtagene autoleucel (satri-cel), a CAR T-cell product candidate targeting Claudin18.2, have been accepted for oral presentation at the 2025 ASCO Annual Meeting. This development highlights the potential of satri-cel as a first-in-class treatment for Claudin18.2-positive solid tumors, particularly in advanced gastric and gastroesophageal junction adenocarcinoma. The acceptance of the abstract underscores CARsgen’s progress in clinical trials and its strategic positioning in the biopharmaceutical industry, potentially impacting stakeholders by advancing treatment options for challenging cancers.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Limited is a biopharmaceutical company specializing in the development of innovative CAR T-cell therapies aimed at addressing unmet clinical needs in areas such as hematologic malignancies, solid tumors, and autoimmune diseases. The company has established comprehensive capabilities in CAR T-cell research and development, including target discovery, preclinical research, clinical development, and commercial-scale production. CARsgen is committed to advancing cell therapies globally, focusing on improving safety, efficacy, and cost-effectiveness.
YTD Price Performance: 71.34%
Average Trading Volume: 7,628,833
Technical Sentiment Signal: Sell
Current Market Cap: HK$9.03B
For a thorough assessment of 2171 stock, go to TipRanks’ Stock Analysis page.